Empagliflozin 10 MG Oral Tablet [Jardiance]

DRUG3 trials

Sponsors

Ain Shams University, Christian Schulze, University of Minnesota

Conditions

Acute Decompensated Heart Failure (ADHF)DiabetesDiabetes MellitusPartial Islet FunctionPharmacodynamicsPharmacokineticsTPIAT

Phase 1

The Effect of Morning Versus Evening Administration on The Pharmacokinetics and Pharmacodynamics of Empagliflozin

CompletedNCT03895229

Ain Shams UniversityDiabetes Mellitus, Pharmacodynamics, Pharmacokinetics

Start: 2018-10-01End: 2018-10-26Updated: 2019-04-02

Phase 3

Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure

RecruitingNCT07038356

Christian SchulzeAcute Decompensated Heart Failure (ADHF)

Start: 2025-12-08End: 2027-06-30Target: 536Updated: 2026-08-26

Phase 4

SGLT2i Therapy in Islet Transplantation (SIT)

RecruitingNCT07228195

University of MinnesotaDiabetes, Partial Islet Function, TPIAT

Start: 2026-07-21End: 2028-12-01Target: 40Updated: 2026-07-22

Related Papers

The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial.

2021-04-264 citations